

The Pharmacogene Variation (PharmVar) Consortium is a central repository for pharmacogene (PGx) variation that focuses on haplotype structure and allelic variation.

The information in this resource facilitates the interpretation of pharmacogenetic test results to guide precision medicine.



Andrea Gaedigk, MS, PhD

Professor Children's Mercy Research Institute, Kansas City University of Missouri-Kansas City Director, PharmVar













IMPROVEMENT May 20, 2024

Variant Frequencies

- The frequency of a variant displayed in the Variant Window is now directly sourced from the latest version of gnomAD
- The frequency provided here represents the global frequency of the variant which may considerably vary across populations
- Information regarding variant frequencies can now also easily be accessed via the external resources link to the PharmGKB SNP page
- Please note that the frequency of a variant does not reflect the frequency of a haplotype (or star allele) if it is part of two or more haplotypes

NEW April 18, 2024

Database Updated to Version 6.1.2

CYP2D6

The Pharmacogene Variation (PharmVar) Consortium is a pharmacogene (PGx) variation that focuses on haplotype

The information in this resource facilitates basic and clin

interpretation of pharmacogenetic test results to guide pr

 "27.001 now fully characterized; evidence level upgraded to 'Definitive'

 Addition of wo novel *27suballeles, *27.002 and *27.003

3. *27.002 was found as a 'singleton' gene and in an identical *27.002x2 duplication configuration

4. *41.005 was corrected (see Change Log document for details)



Database Updated to Version 6.1


New gene: NAT2

NAT2 nomenclature was transferred from from the original <u>Database of Arylamine N-</u> <u>Acetyltransferases</u> to PharmVar on March 11, 2024.

PharmVar

Pharmacogene Variation Consortium


(1) PharmVar API Services are now available for third party use. For more information, visit the API Service Documentation Page



PharmVar Publications

Articles published by PharmVar are available on the resources page.

PharmVar



gene pages

RefSeq	5' limit	5' limit	3' limit	3' limit	
	Counting from the	Counting from the	Counting from the	Counting from the	
	sequence start	ATG translation start	sequence start	ATG translation start	
NG_008376.4	3436	-1584	9501	4482	
All SNVs within the 5' and 3' limits must be submitted for haplotype (star allele) definitions.					
This includes 5' flanking sequence, the 5' UTR, exons 1-9, introns 1-8, the 3' UTR, and the 3'					
flanking sequence.					

Download Gene Data 🚽


Additional Data Download Information

₹ III

PharmVar

deposited by now has "year" the allele was posted

citations



 Coming: more info about depositing author(s) in Change Log document

PharmVar Variant Frequencies

CYP2D6*10

100C>T (<u>rs1065852</u>, P34S)

4181G>C

Variant Positions

Gene	NG_008376.4:g.5119C>T				
Transcript		NM_000106.6	5:c.1(00C>T	
GRCh37	NC_000022.10:g.42526694G>A				
GRCh38	NC_000022.11:g.42130692G>A				
Reference Sequence	Position	Reference		Variant	
NG_008376.4					
Sequence Start	5119	С	>	т	
ATC Start	100	С	>	т	
NM_000106.6					
Seguence Start	119	С	>	т	
ATG Start	100	с	>	т	
GRCh37 (NC_000022.	10)				

Show Haplotypes With This Variant

External Resources:

<u>dbSNP:rs1065852</u> <u>PharmGKB:PA166156062</u> <u>GnomAD:rs1065852</u>

Variant Frequency:

0.212157 (GnomAD)

PharmVar Variant Frequencies

link to PharmGKB variant/SNP page

°=° rs1065852

gnomAD Genome •	gnomAD Exome •	1000 Genomes •	ALFA •	A CONTRACTOR OF	PHARMGKB
-----------------	----------------	----------------	--------	---	----------

Based on v3 genome data from the Genomes Aggregation Database (gnomAD) retrieved from the Ensembl API.



This SNP is presents the frequency of <u>ALL</u> star alleles including *4 and *10

PharmVar Allele Window



More info cominglink to PharmGKBhaplotype page

││ CYP2D6*10

CPIC UK Biobank			
Based on <u>CPIC Frequency Tab</u>	<u>ples</u> .		
POPULATION ()	CYP2D6*10 OBSERVED 🖨	ALLELES TOTAL 🗢	FREQUENCY 🖨
African American/Afro-Caribb	pean 777	20368	3.82%
American	127	8768	1.45%
Central/South Asian	339	4488	7.56%
East Asian	16973	39616	42.84%
European	1750	111390	1.57%
Latino	423	16098	2.63%
Near Eastern	313	4626	6.77%
Oceanian	114	1998	5.71%
Sub-Saharan African	220	4518	4.87%

DPYD

Get-RM study

Reference Materials

AMP Clinical testing recommendations

Characterization of Reference Materials for DPYD – A GeT-RM Collaborative Project

Gaedigk, Turner, Moyer, Zubiaur, Boone, Wang, Broeckel and Kalman J Mol Diag, in revision

DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the AMP, ACMG, CPIC, American Pathologists, DPWG, ESPG, PharmGKV and PharmVar

Pratt, Cavallari, Fulmer, Gaedigk, Hachad, Ji, Kalman, Ly, Moyer, Scott, Turner, van Scaik, Whirl-Carrillo and Weck

J Mol Diag, accepted

GeT-RM PGx Search Tool

coriell.org/GetRM/PGxSearch

Consensus genotypes covering

- 334 Coriell DNA samples
- 8 GeT-RM studies
- 34 genes/loci

Systems *Coriell Institute for Medical Research, Camden NJ, *Agena Bioscience, San Diego, CA, *Children's Mercy Research Institute (CMRI), Division of Clinical Pharm Wisconsin, Department of Pediatrics, Section on Genomic Pediatrics, Milwaukee, WI, *Department of Laboratory Medicine and Pathology, Mayo Clinic, Roc Laboratory Systems, Centers for Disease Control and Prevention, Atlanta GA Introduction Result Regulations, accreditation standards, and professional guidance require laboratories to use reference materials for assay development, validation, A consolidated information resource containing consensus genotypes covering 334 DNA samples characterized during 8 GeT-RM PGx or HLA studies for 34 genes/loci (Tables 1 and 2) including CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP2D6, TMPT, NUDT15, DPYD, and 11 HLA loci is available as an Excel file on the quality control, and proficiency testing of clinical genetic tests. There are, GeT-RM website (Figure 1). A searchable web-based database too GeT-RM PGx Search, is available at https://www.coriell.org/GeTRM/PGxSearch. Figure displays a screen shot of GeT-RM PGx Search. This example displays results for CVP2D6, chosen from the dropdown filter on the top of the table. Results however, very few publicly available reference materials for most genetic tests. To address this issue, the Centers for Disease Control and Prevention's for each gene can be filtered by allele. The reference (Table 2) for each genotype is provided in the adjacent column. Links to PharmVar and the NCBI entry Genetic Testing Reference Material Program (GeT-RM), the Coriell Institute for the selected gene are provided. The GeT-RM PGx Search results can be exported to a CSV file by clicking the green button on the right side of the page. for Medical Research, and the genetic testing community have conducted 0 19 studies to create characterized and publicly available DNA samples for use as reference materials, including 8 for pharmacogenetic (PGx) and Figure 1. Screenshot of the consolidated Excel file available on the GeT-RM website Human Leukocyte Antigen (HLA) testing. This information is available in Figure 1. Excel file shows two new resources containing all available PGx and HLA genotypes for 334 NHGRI repositories at the Coriell Institute for consensus genotypes for 34 samples. Medical Research gene/loci determined during Methods 8 GeT-RM studies (Table 2). References for each For each GeT-RM study, cell line DNA samples containing possible PGx genotype are provided in the variants of interest were selected from the National Institute of General adiacent column. BAM and Medical Sciences (NIGMS) Human Genetic Cell Repository and/or the FASTO files are available for National Human Genome Research Institute (NHGRI) Sample Repository some samples, and many for Human Genetic Research at the Coriell Institute for Medical Research *1/*6 *1/*1 *1/*1 *1/*1 *6(*27) *6(*27) have sequence data from the Each sample was characterized using a variety of methods and test 1000 Genomes Project. platforms in 2 or more laboratories Results were assessed for quality, discordances, and determination of consensus genotype for each sample These data were used to create consolidated information resources Coriell GeT-RM PGx Search Figure 2. Screenshot of searchable web-based database, GeT-RM PGx Search Table 1. Genes/loci in the GeT-RM Excel and searchable database CYP1A1 • CYP2D6 • GSTP1 • SLCO1B1 • HLA-A • HLA-DQA1 GeT-RM PGx Search Res Figure 2. Search by gene and allele to return CYP1A2 · CYP2E1 · GSTT1 · SLCO2B1 · HLA-B · HLA-DQB1 Gene: (CP206 an interactive table of each sample, CYP2A6 · CYP3A4 · NAT1 · TPMT · HLA-C · HLA-DPA1 CYP2B6 • CYP3A5 • NAT2 UGT1A1 • HLA-DRB1 • HLA-DPB1 genotype, and subject population descriptor, CYP2C8 · CYP4F2 · NUDT15 · UGT2B7 · HLA-DRB3 that can be further filtered or exported to an CYP2C9 • DPYD • SLC15A2 • UGT2B15 • HLA-DRB4 Excel file. CYP2C19 · GSTM1 · SLC22A2 · UGT2B17 · HLA-DRB5 CYP2C Cluster NC 000010.10: g.96405502G>A, rs1277782 GGCX NM_000821.6:c.214+597G>A, rs12714145 GGCX NM_000821.6:c.2084+45G>C rs11676382 when which when we Breek (s. a. 52 2 a. s Table 2, References for consolidated Excel file (Figure 1) and GeT-RM PGx Search (Figure 2) VKORC1 NM 024006 5:c -1639654 rt9923231 Reference # Product # Source VKORC1 NM 024006.6:c.106G>A, rs6174224 VKORC1 NM 024006.6:c.196G>A, rs7254752 1. Pratt et al., J Mol Diagn (2010) 12(6):835-846 2. Pratt et al., J Mol Diagn (2016) 18(1):109-123 3. Gaedigk et al., J Mol Diagn (2019) 21(6):1034-1052 4. Gaedigk et al., J Mol Diagn (2022) 24(4):337-350 10. GeT-RM 5. Pratt et al., J Mol Diagn (2021) 23(8):952-958 CDO 6. Pratt et al., J Mol Diagn (2022) 24(10):1079-1088 Gaedigk et al., J Mol Diagn (2023) 25(9):655-664

Characterized DNA Reference Materials for PGx and HLA Testing:

The Genetic Testing Reference Material (GeT-RM) Program

Scheinfeldt L¹, Kusic D¹, Pratt VM², Gaedigk A³, Turner AJ⁴, Moyer AM⁵, Whirl-Carrillo M⁶, Kalman LV⁷

Division of

Laboratory



a a 🚺 🖹 a

8. Bettinotti et al., J Mol Diagn (2018) 20(5):703-71

Conclusions

These resources provide an easily accessible way to find information about publicly available, well-characterized DNA samples that can be used to support test development and quality assurance programs of laboratories performing clinical PGx and HLA testing. All reference materials developed by GeT-RM are publicly available from the NIGMS and

GeT-RM Website



https://www.cdc.gov/labquality/get-rm/index.html Info about RMs characterized by GeT-RM Links to GeT-RM publications

> CONTACT INFO Lisa Kalman PhD LKalman@cdc.gov

PharmVar publications



Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation

2021

Please cite!

Andrea Gaedigk^{1,2,*}, Scott T. Casey³, Michelle Whirl-Carrillo⁴, Neil A. Miller³ and Teri E. Klein^{4,5}

2023

PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting

Amy J. Turner^{1,2}, Charity Nofziger³, Bronwyn E. Ramey⁴, Reynold C. Ly⁵, Chad A. Bousman⁶, José A. G. Agúndez^{7,8}, Katrin Sangkuhl⁹, Michelle Whirl-Carrillo⁹, Simone Vanoni³, Henry M. Dunnenberger¹⁰, Gualberto Ruaño^{11,12}, Martin A. Kennedy¹³, Michael S. Phillips¹⁴, Houda Hachad¹⁵, Teri E. Klein¹⁶, Ann M. Moyer¹⁷, and Andrea Gaedigk^{18,19,*}



PharmVar GeneFocus: CYP2A6 (in revision)

PharmVar GeneFocus: CYP4F2 (submitted)

PharmVar GeneFocus: NAT2 (initiated)

CYP2D6 this panel keeps busy...

CYP2D6 Gene Expert Panel			
Role	Name	Institution	Country
Chair	Andrea Gaedigk	Children's Mercy/PharmVar	USA
Vice Chair	Houda Hachad	AccessDx	USA
PharmVar Representative	Michael Phillips	Precision Medicine Advisers	Canada
PharmGKB/CPIC Representative	Teri Klein	Stanford, PharmGKB	USA
PharmGKB/CPIC Representative	Katrin Sangkuhl	Stanford, PharmGKB	USA
PharmGKB/CPIC Representative	Michelle Whirl-Carrillo	Stanford, PharmGKB	USA
Member	Jose Agundez	Universidad de Extremadura	Spain
Member	Chad Bousman	University of Calgary	Canada
Member	Mark Dunnenberger	NorthShore University HealthSystem	USA
Member	Martin Kennedy	University of Otago	New Zealand
Member	Reynold Ly	Nationwide Children's Hospital	USA
Member	Ann Moyer	Mayo Clinic	USA
Member	Charity Nofziger	PharmGenetix GmbH	Austria
Member	Bronwyn Ramey	Let's Get Checked	USA
Member	Gualberto Ruano	Institute of Living at Hartford Hospital	USA
Member	Amy Turner	Medical College of Wisconsin; RPRD Diagnostics, LLC	USA

CYP2D6 expert panel

- New star alleles, suballeles and structural variants keep coming
- o "Clean-up" efforts
 - Looking into alleles with limited evidence that were first defined using methods we would not accept today
 - Confirmed *27, there are now three suballeles, one found as *27.002x2
 - Need to confirm *20, *23, *24, *25, *26, *30, *34, *37 and some *2, *3, *4, *6, *12, *19 suballeles
 - Concerns that some of these alleles do not exist as defined
 - Retire some alleles if no evidence can be found in the literature or databases supporting the allele in question?
 - Can we identify samples with SNV(s) of interest for reanalysis?

If you have data for alleles with a "Limited" or "Moderate" evidence level, please consider submitting to PharmVar

CYP1A2 curation underway

CYP1A2 Gene Expert Panel					
Role	Name	Institution	Country		
Chair	Andrea Gaedigk	Children's Mercy Research Institute	USA		
Vice Chair	Pablo Zubiaur	Universidad Autonoma de Madrid	Spain		
PharmGKB/CPIC Representative	Michelle Whirl-Carrillo	Stanford, PharmGKB	USA		
PharmGKB/CPIC Representative	Teri Klein	Stanford, PharmGKB	USA		
Member	Solomon Adams	Base5	USA		
Member	Matthias König	Humboldt University	Germany		
Member	Dora Koller	University of Barcelona	Spain		
Member	Volker Lauschke	Karolinska Institutet and Institute of Clinical Pharmacology	Sweden, Germany		
Member	Martin Lewis	South Australia Health & Medical Research Institute, Adelaide	Australia		
Member	Katalin Monostory	HUN-REN Research Centre for Natural Sciences	Hungary		
Member	Mohamed Nagy	Children's Cancer Hospital	Egypt		
Member	Amy Turner	Medical College of Wisconsin; RPRD Diagnostics, LLC	USA		
Member	David Twesigomwe	Brenner Institute, University of the Witwatersrand	South Africa		
Trainee	Gonzalo Villapalos- Garcia	Hospital Universitario de La Princesa and Children's Mercy Research Institute	Spain, USA		
Data Specialist	Erin Boone	Children's Mercy Research Institute	USA		
Ad Hoc Member	Chad Bousman	University of Calgary	Canada		

$\circ~$ No CPIC or DPWG guidelines

- PharmGKB PharmGKB level 3/4
- PharmVar Priority Level low

• Tested by many PGx panels


- \circ Many star alleles poorly characterized
- Many common haplotypes not defined

Major changes are coming Fall 2024

CYP1a2 expert panel

NAT2 transferred from the NAT database to PharmVar!

- PharmVar NAT2 gene page launched in March 2024
- NAT2 "legacy" content still available at the DUTH site
- *NAT1* and non-human *NATs* will continue to be hosted by DUTH



Big "Thank You" to all who provided *NAT2* nomenclature in the past and/or served on the PharmVar expert panel to make the transition happen

used for the CPIC guideline on *NAT2* and hydralazine

NAT2 Gene Expert Panel			
Role	Name	Institution	Country
Chair	Andrea Gaedigk	Children's Mercy Research Institute	USA
Chair	Sotiria (Rea) Boukouvala	Democritus University of Thrace	Greece
PharmGKB/CPIC Representative	Michelle Whirl-Carrillo	Stanford, PharmGKB	USA
PharmGKB/CPIC Representative	Katrin Sangkuhl	Stanford, PharmGKB	USA
PharmGKB/CPIC Representative	Teri Klein	Stanford, PharmGKB	USA
Member	Jose Agundez	Universidad de Extremadura	Spain
Member	Giannoulis Fakis	Democritus University of Thrace	Greece
Member	Mariam Habil	University of Louisville	USA
Member	David Hein	University of Louisville	USA
Member	Rod Minchin	University of Queensland	Australia
Trainee	Georgia Papanikolaou	Democritus University of Thrace	Greece
Member	Estella Poloni	University of Geneva	Switzerland
Member	Adalberto Rezende Santos	Oswaldo Cruz Foundation	Brazil
Member	Raquel Teixeira	Laboratório de Biologia Molecular Aplicada a Micobactérias	Brazil
Data Specialist	Erin Boone	Children's Mercy Research Institute	USA

- Allele definitions include the 5' and 3' untranslated regions
- Star allele definitions use NG_012246.1
- The "new" NAT2*1 allele matches
 NG_012246.1 and GRCh38 (and the "old" *12A)
- Used 1000 Genomes 30X WGS data to confirm existing allele definitions (and discover some new ones)
- Not all previously defined star alleles were transferred to PharmVar
- Many were assigned a new star allele
 number to conform with PharmVar rules

NAT2 expert panel

NAT2


Alleles not transferred

- Numerous alleles defined based on computational inference
- $\circ~$ Papers provide limited/no information about
 - o about method
 - SNPs present in subjects(s) with "new" haplotype
 - Possible/alternate diplotype
 - $\circ~$ Inferred to be present in one/few subjects
- $\circ~$ Concerns about whether these exist
- Efforts underway by panel experts to reanalyze samples, if available
- Experts concurred that experimental validation is needed before transfer to
 PharmVar to ensure high-quality content of *NAT2* star alleles in PharmVar


NAT2

Renamed alleles

to conform to PharmVar rules



Look it up!





NATZ					
External Resources	PHARMG <mark>KB</mark>	<u>ClinGen</u>	<u>ClinVar</u>	EntrezGene	HGNC
E Read Me for NAT2	A Change Log fo	r NAT2	+ More	Documents	

Look-up table

Legacy name	PharmVar Name ¹	Transferred Yes/No ▼	PharmVar data base version if transferred OR why allele was not transferred
*10	*10.001	yes	6.1 (March 11, 2024)
*11A	*4.002	yes	6.1 (March 11, 2024)
*12A	*1.001	yes	6.1 (March 11, 2024)
*12B	*1.002	yes	6.1 (March 11, 2024)
*12C	*1.003	yes	6.1 (March 11, 2024)
*12D	*48.001	yes	6.1 (March 11, 2024)
*12E	*41.001	yes	6.1 (March 11, 2024)
*11B	n/a	no	allele retired from NAT nomenclature site
*12K	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*12L	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*12M	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*13B	*13 reserved	no	evidence review in progress; if transferred, allele will keep its original star number
*13C	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar

NAT2					
External Resources	PHARMG KB	<u>ClinGen</u>	<u>ClinVar</u>	EntrezGene	HGNC
Read Me for NAT2	A Change Log fo	r NAT2	+ More	Documents	

Look-up table

Legacy	PharmVar	Transferred Yes/No	PharmVar data base version if transferred OR why allele was not transferred
name	Name ¹		
*10	*10.001	yes	6.1 (March 11, 2024)
*11A	*4.002	yes	6.1 (March 11, 2024)
*12A	*1.001	yes	6.1 (March 11, 2024)
*12B	*1.002	yes	6.1 (March 11, 2024)
*12C	*1.003	yes	6.1 (March 11, 2024)
*12D	*48.001	yes	6.1 (March 11, 2024)
*12E	*41.001	yes	6.1 (March 11, 2024)
*11B	n/a	no	allele retired from NAT nomenclature site
*12K	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*12L	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*12M	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*13B	*13 reserved	no	evidence review in progress; if transferred, allele will keep its original star number
*13C	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar

NATZ					
External Resources	🕺 PHARMG KB	<u>ClinGen</u>	<u>ClinVar</u>	EntrezGene	HGNC
-					
Read Me for NAT2	A Change Log fo	r NAT2	+ More	Documents	

Look-up table

Legacy name	PharmVar Name ¹ ▼	Transferred Yes/No	PharmVar data base version if transferred OR why allele was not transferred
*10	*10.001	yes	6.1 (March 11, 2024)
*11A	*4.002	yes	6.1 (March 11, 2024)
*12A	*1.001	yes	6.1 (March 11, 2024)
*12B	*1.002	yes	6.1 (March 11, 2024)
*12C	*1.003	yes	6.1 (March 11, 2024)
*12D	*48.001	yes	6.1 (March 11, 2024)
*12E	*41.001	yes	6.1 (March 11, 2024)
*11B	n/a	no	allele retired from NAT nomenclature site
*12K	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*12L	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*12M	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar
*13B	*13 reserved	no	evidence review in progress; if transferred, allele will keep its original star number
*13C	n/a	no	computationally inferred; experimental evidence needed to confirm haplotype and transfer to PharmVar

TPMT? ABCG2? VCORC1? UGT1A1? Other?

Can't do this without

Gene Champions and Experts



及Thank You Köszönöm Tack Спасибо Dank Gracias 街街 Merci ありがとう

Supported by the Children's Mercy Research Institute

NIH> NIGMS R24GM123930 (2017-2021)

PharmVar

Scott Casey (website developer) Erin Boone (data) Wendy Wang (lab, submissions) Expert Panelists Submitters

PharmGKB CPIC

GeT-RM AMP

Teri Klein Michelle Whirl-Carrillo Kelly Caudle and all curators Lisa Kalman Vicky Pratt